HMGN2P19

Across TCGA pan-cancer cohorts, HMGN2P19 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of HMGN2P19’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where HMGN2P19 RNA is repressed in tumor relative to normal tissue. In most cancer types HMGN2P19 is over-expressed in tumor, although a few such as BLCA and THCA show the opposite, repressed pattern.

BLCA, THCA, and BRCA are the cancer types where HMGN2P19 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HMGN2P19 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	−1.847	<.001	12	view →
THCA	Female	II,III,IV	−0.582	<.001	11	view →
BRCA	All	II,III,IV	−0.222	<.001	6	view →
KICH	All	All	−0.206	<.001	5	view →
COAD	All	All	−0.201	.029	3	view →
LUSC	All	All	−0.179	.011	3	view →
PRAD	All	All	−0.567	<.001	2	view →
UCEC	All	All	−0.400	.025	2	view →
LIHC	All	All	+0.096	.007	2	view →
LUAD	Male	All	−0.223	.029	1	view →
KIRC	Male	All	+0.075	.047	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

HMGN2P19–BLCA

Open the BLCA breakdown →